Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon.
Alpha interferons have become effective palliative treatments for patients with neuroendocrine tumours such as carcinoids and endocrine pancreatic tumours. However, several reports indicate an increased incidence of both autoantibodies and autoimmune diseases in patients treated with interferon-alpha (IFN-alpha). We studied the development of antibodies against double-stranded DNA (dsDNA) and clinical signs of autoimmune disease in 214 patients with malignant carcinoids or endocrine pancreatic tumours consecutively admitted for treatment with IFN-alpha. Seventeen patients (8%) developed antibodies against dsDNA, predominantly females (12 females and 5 males). One patient had clinical and laboratory signs of polymyositis. Among the other 16 patients, three developed hypothyroidism and in six patients the anti-dsDNA autoantibodies normalized despite continuing therapy. Although a significant number of patients developed autoantibodies against dsDNA, overt autoimmune disease related to these antibodies is a rare event and many patients spontaneously normalize these titres despite continuing IFN-alpha treatment.
Kälkner
K M
KM
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Rönnblom
L
L
Karlsson Parra
A K
AK
Bengtsson
M
M
Olsson
Y
Y
Oberg
K
K
D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood*; D001327:Autoimmune Diseases / Q000209:etiology* / Q000473:pathology; D002276:Carcinoid Tumor / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D017285:Polymyositis / Q000209:etiology* / Q000473:pathology
D000974:Antibodies, Antinuclear; D016898:Interferon-alpha